227 related articles for article (PubMed ID: 26046674)
21. Effect of nitric oxide synthase on multiple drug resistance is related to Wnt signaling in non-small cell lung cancer.
Li Y; Ma C; Shi X; Wen Z; Li D; Sun M; Ding H
Oncol Rep; 2014 Oct; 32(4):1703-8. PubMed ID: 25070480
[TBL] [Abstract][Full Text] [Related]
22. MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity
Son DJ; Zheng J; Jung YY; Hwang CJ; Lee HP; Woo JR; Baek SY; Ham YW; Kang MW; Shong M; Kweon GR; Song MJ; Jung JK; Han SB; Kim BY; Yoon DY; Choi BY; Hong JT
Theranostics; 2017; 7(18):4632-4642. PubMed ID: 29158850
[No Abstract] [Full Text] [Related]
23. Smurf2-Mediated Stabilization of DNA Topoisomerase IIα Controls Genomic Integrity.
Emanuelli A; Borroni AP; Apel-Sarid L; Shah PA; Ayyathan DM; Koganti P; Levy-Cohen G; Blank M
Cancer Res; 2017 Aug; 77(16):4217-4227. PubMed ID: 28611047
[TBL] [Abstract][Full Text] [Related]
24. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response.
Guinee DG; Holden JA; Benfield JR; Woodward ML; Przygodzki RM; Fishback NF; Koss MN; Travis WD
Cancer; 1996 Aug; 78(4):729-35. PubMed ID: 8756364
[TBL] [Abstract][Full Text] [Related]
25. Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor.
Kadayat TM; Park C; Jun KY; Thapa Magar TB; Bist G; Yoo HY; Kwon Y; Lee ES
Eur J Med Chem; 2015 Jan; 90():302-14. PubMed ID: 25437617
[TBL] [Abstract][Full Text] [Related]
26. Regulation of the catalytic function of topoisomerase II alpha through association with RNA.
Park SW; Parrott AM; Fritz DT; Park Y; Mathews MB; Lee CG
Nucleic Acids Res; 2008 Nov; 36(19):6080-90. PubMed ID: 18820297
[TBL] [Abstract][Full Text] [Related]
27. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
28. Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.
Dickey JS; Osheroff N
Biochemistry; 2005 Aug; 44(34):11546-54. PubMed ID: 16114891
[TBL] [Abstract][Full Text] [Related]
29. A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2.
Kim HL; Jeon KH; Jun KY; Choi Y; Kim DK; Na Y; Kwon Y
Cancer Lett; 2012 Dec; 325(1):72-9. PubMed ID: 22732416
[TBL] [Abstract][Full Text] [Related]
30. Combination of low concentration of (-)-epigallocatechin gallate (EGCG) and curcumin strongly suppresses the growth of non-small cell lung cancer in vitro and in vivo through causing cell cycle arrest.
Zhou DH; Wang X; Yang M; Shi X; Huang W; Feng Q
Int J Mol Sci; 2013 Jun; 14(6):12023-36. PubMed ID: 23739680
[TBL] [Abstract][Full Text] [Related]
31. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
32. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
33. Paired box 5 is a frequently methylated lung cancer tumour suppressor gene interfering β-catenin signalling and GADD45G expression.
Zhao L; Li S; Gan L; Li C; Qiu Z; Feng Y; Li J; Li L; Li C; Peng W; Xu C; Wang Z; Hui T; Ren G; Tao Q; Xiang T
J Cell Mol Med; 2016 May; 20(5):842-54. PubMed ID: 26843424
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
35. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
[TBL] [Abstract][Full Text] [Related]
36. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
[TBL] [Abstract][Full Text] [Related]
37. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
38. D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα.
Gui M; Shi DK; Huang M; Zhao Y; Sun QM; Zhang J; Chen Q; Feng JM; Liu CH; Li M; Li YX; Geng M; Ding J
Invest New Drugs; 2011 Oct; 29(5):800-10. PubMed ID: 20336347
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Guo L; Liu X; Nishikawa K; Plunkett W
Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
[TBL] [Abstract][Full Text] [Related]
40. Interaction between tumor suppressor adenomatous polyposis coli and topoisomerase IIalpha: implication for the G2/M transition.
Wang Y; Azuma Y; Moore D; Osheroff N; Neufeld KL
Mol Biol Cell; 2008 Oct; 19(10):4076-85. PubMed ID: 18632987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
